Document is current
Any future updates will be listed below
-
Authors
Majzoub, Marwan E. https://orcid.org/0000-0001-6461-8211
Paramsothy, Sudarshan
Haifer, Craig
Parthasarathy, Rohit https://orcid.org/0000-0002-9405-352X
Borody, Thomas J. https://orcid.org/0000-0002-0519-4698
Leong, Rupert W.
Kamm, Michael A.
Kaakoush, Nadeem O. https://orcid.org/0000-0003-4017-1077
-
Funding
Funding for this research was provided by:
Crohn's and Colitis Foundation (988415)
Department of Health | National Health and Medical Research Council (APP2011047, Investigator grant)
University of New South Wales (Scientia fellowship)
- License Information
-
More Information
Article History
Received: 16 June 2024
Accepted: 8 October 2024
First Online: 17 October 2024
Competing interests
: SP has served as a consultant for Vedanta Biosciences and has received speaker / advisory board fees from AbbVie, Dr Falk Pharma, Ferring, Janssen and Takeda. CH has served on an advisory board for BiomeBank, Abbvie and Takeda and has received speaker fees /education support from Pfizer, Dr Falk Pharma, Ferring, Janssen, Takeda and Abbvie. TJB has a pecuniary interest in the Centre for Digestive Diseases, is a medical advisor to RedHill Bio and Topelia Aust, and holds patents in FMT treatment. RWL reports personal fees from AbbVie, personal fees from Aspen, personal fees from Ferring, grants and personal fees from Hospira/ Pfizer, grants and personal fees from Janssen, grants and personal fees from Takeda, grants from Shire, personal fees from Celgene, personal fees from Dr Falk Pharma, personal fees from Novartis, personal fees from MSD, personal fees from Chiesi, personal fees from BMS, personal fees from Glutagen, outside the submitted work. All other authors have no conflicts of interest to declare.
